Molecular indicators of surface and bulk instability of hot melt extruded amorphous solid dispersions

Pharmaceutical Research

Volumn 32, Issue 4, 2015, Pages 1210-1228

  Yang, Ziyi ^a,c   Nollenberger, Kathrin ^b   Albers, Jessica ^b   Craig, Duncan ^c   Qi, Sheng ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b EVONIK INDUSTRIES AG   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

amorphous molecular dispersions; hot melt extrusion; molecular mobility; physical stability; surface crystallization

Indexed keywords

CARBAMAZEPINE; CELECOXIB; EUDRAGIT; FELODIPINE; FENOFIBRATE; DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; GLASS TRANSITION TEMPERATURE; HOT MELT EXTRUSION; HUMIDITY; INFRARED SPECTROSCOPY; KINETICS; MISCIBILITY; PARAMETERS; PELLET EXTRUSION; PHASE SEPARATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID; SOLID DISPERSION; TEMPERATURE STRESS; THERMODYNAMICS; X RAY POWDER DIFFRACTION; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; HEAT; MEDICINAL CHEMISTRY; POLARIZATION MICROSCOPY; PROCEDURES; SOLUBILITY; SURFACE PROPERTY; TRANSITION TEMPERATURE; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; HOT TEMPERATURE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, POLARIZATION; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PHENOMENA; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TRANSITION TEMPERATURE; X-RAY DIFFRACTION;

EID: 84924678523     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1527-8     Document Type: Article

References (36)

1. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88:1058-66.
2. Leunerand C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47-60.
3. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:27-42.
4. Qi S, Gryczke A, Belton P, Craig DQM. Characterisation of solid dispersions of paracetamol and EUDRAGIT® E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int J Pharm. 2008;354:158-67.
5. Qi S, Belton P, Nollenberger K, Clayden N, Reading M, Craig DM. Characterisation and prediction of phase separation in hot-melt extruded solid dispersions: a thermal. Microscopic and NMR Relaxometry Study. Pharm Res. 2010;27:1869-83.
6. Hancock B, Shamblin S, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995;12:799-806.
7. Marsac P, Shamblin S, Taylor L. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res. 2006;23:2417-26.
8. Marsac P, Li T, Taylor L. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res. 2009;26:139-51.
9. Qi S, Craig DM. Detection of phase separation in hot melt extruded solid dispersion formulations global vs. localized characterization. Am Pharm Rev. 2010;13:68-74.
10. Qian F, Huang J, Hussain MA. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99:2941-7.
11. Rumondorand ACF, Taylor LS. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol Pharm. 2009;7:477-90.
12. Mahieu A, Willart J-F, Dudognon E, Danède F, Descamps M. A new protocol to determine the solubility of drugs into polymer matrixes. Mol Pharm. 2012;10:560-6.
13. Yang Z, Nollenberger K, Albers J, Qi S. Molecular implications of drug-polymer solubility in understanding the destabilization of solid dispersions by milling. Mol Pharm. 2014;11:2453-65.
14. Hancockand BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86:1-12.
15. Ng YC, Yang Z, McAuley WJ, Qi S. Stabilisation of amorphous drugs under high humidity using pharmaceutical thin films. Eur J Pharm Biopharm. 2013;84:555-65.
16. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, et al. Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev Ind Pharm. 2007;33:1043-57.
17. Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. Int J Pharm. 2012;429:58-68.
18. Maniruzzaman M, Rana MM, Boateng JS, Mitchell JC, Douroumis D. Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers. Drug Dev Ind Pharm. 2013;39:218-27.
19. Ke P, Hasegawa S, Al-Obaidi H, Buckton G. Investigation of preparation methods on surface/bulk structural relaxation and glass fragility of amorphous solid dispersions. Int J Pharm. 2012;422:170-8.
20. Qi S, Moffat JG, Yang Z. Early stage phase separation in pharmaceutical solid dispersion thin films under high humidity: improved spatial understanding using probe-based thermal and spectroscopic nanocharacterization methods. Mol Pharm. 2013;10:918-30.
21. Yang Z, Nollenberger K, Albers J, Moffat JG, Craig DQM, Qi S. The effect of processing on the surface physical stability of amorphous solid dispersions. Eur J Pharm Biopharm. 2014. Accepted.
22. Nishiand T, Wang TT. Melting point depression and kinetic effects of cooling on crystallization in poly(vinylidene fluoride)-poly(methyl methacrylate) mixtures. Macromolecules. 1975;8:909-15.
23. Andronisand V, Zografi G. The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity. Pharm Res. 1998;15:835-42.
24. Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci. 1994;83:1700-5.
25. Qi S, Avalle P, Saklatvala R, Craig DQM. An investigation into the effects of thermal history on the crystallisation behaviour of amorphous paracetamol. Eur J Pharm Biopharm. 2008;69:364-71.
26. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm. 2008;5:927-36.
27. Hodge IM. Strong and fragile liquids - a brief critique. J Non-Cryst Solids. 1996;202:164-72.
28. Bhattacharyaand S, Suryanarayanan R. Local mobility in amorphous pharmaceuticals - characterization and implications on stability. J Pharm Sci. 2009;98:2935-53.
29. Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99:3787-806.
30. Van Eerdenbrugh B, Baird JA, Taylor LS. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation - classification and comparison with crystallization tendency from undercooled melts. J Pharm Sci. 2010;99:3826-38.
31. Surana R, Pyne A, Suryanarayanan R. Effect of aging on the physical properties of amorphous trehalose. Pharm Res. 2004;21:867-74.
32. Floryand PJ, Krigbaum WR. Thermodynamics of high polymer solutions. Annu Rev Phys Chem. 1951;2:383-402.
33. Rustichelli C, Gamberini G, Ferioli V, Gamberini MC, Ficarra R, Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal. 2000;23:41-54.
34. Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci. 2003;92:2260-71.
35. Avrami M. Kinetics of phase change. I General theory. J Chem Phys. 1939;7:1103-12.
36. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci. 2003;20:305-17.